Resultado de búsqueda
Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED. PMID: 23676159. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Clinical Professor. HIV, Infectious Disease, and Global Medicine, Infectious Diseases. Interests: HIV therapeutic strategies, COVID-19 treatment and prevention, Sexually Transmitted Infections, DoxyPEP, Viral hepatitis, Hepatitis C, Hepatitis Elimination. Clinical Trials:
School of Medicine. annie.luetkemeyer@ucsf.edu. +1 415 502-5753. Publications. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial. JAMA network open. Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC.
Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis.
annie.luetkemeyer@ucsf.edu. +1 415 476-4082 ext. 130. I specialize in HIV/AIDS and have clinical responsibilities including outpatient services at the San Francisco General Hospital HIV clinic as well as inpatient services on the HIV/AIDS, general medicine, and infectious diseases consult services. I direct the HIV Clinical Trials Group at SFGH
Annie Luetkemeyer, MD. Email: aluetkemeyer@php.ucsf.edu. CFAR Awards. Comparison of Quantiferon to Conventional Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection (LTBI) in HIV Positive Subjects . Mentored Scientist Award, Spring 2005. Award Mentor: Diane ...
Annie Luetkemeyer, MD, professor of infectious diseases at UCSF, is an expert on the treatment of viral infections. On March 24, 2020, Robert Wachter, MD, chair of the Department of Medicine at UCSF, interviewed her on the evidence behind ...
